NRC Form 374
(3-84)

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Amendment No. 27

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with application dated March 1, 1985
1. Department of the Army USAMEDDAC	3. License number 16-03657-01 is amended in its entirety to read as follows:
2. Ireland Army Community Hospital Fort Knox, Kentucky 40121-5520	4. Expiration date: July 31, 1990
	5. Docket or Reference No.: 030-01748

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radio-pharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A.
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 5 curies of each byproduct material authorized in Subitem 6.B.
C. Any byproduct material listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. Any radio-pharmaceutical listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. As necessary for uses authorized in Subitem 9.C.
D. Any byproduct material listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. Any radio-pharmaceutical listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. As necessary for uses authorized in Subitem 9.D.

MLDO

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 16-03657-01

Docket or Reference number: 030-01748

Amendment No. 27

6. Byproduct, source and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
E. Any byproduct material listed in Section 31.11(a) of 10 CFR 31	E. Any	E. 5 millicuries of each byproduct material authorized in Subitem 6.E.
F. Carbon 14	F. Any	F. 9 millicuries
G. Carbon 14	G. Sealed source	G. 1.6 millicuries
H. Krypton 85	H. Sealed source	H. 5 millicuries

9. Authorized use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

C. Any therapeutic procedure listed in Group IV of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

D. Any therapeutic procedure listed in Group V of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

E. and F. In-vitro studies.

G. For use in performing night vision tests of pilots and other personnel.

H. For use in performing instrument calibrations.

CONDITIONS

10. Licensed material shall be used only at Ireland Army Community Hospital, Fort Knox, Kentucky.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 16-03657-01

Docket or Reference number: 030-01748

Amendment No. 27

(Cont'd) CONDITIONS

11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."

12. Licensed material shall be used by, or under the supervision of, individuals designated by the licensee's Radiation Control Committee.

13. The use of licensed material in or on humans shall be by a physician as defined in 10 CFR 35.3(b).

14. The Radiation Protection Officer for the activities authorized by this license is John G. Manfre, Jr.

15. Licensed material shall be used in accordance with the provisions of Section 35.14(b)(c)(v) and (f) of Title 10, Code of Federal Regulations.

16. Patients containing Iodine 131 for the treatment of thyroid carcinoma shall remain hospitalized until the residual activity is 30 millicuries or less.

17. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:

    A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of ten (10) half-lives.

    B. Prior to disposal as normal waste, radioactive waste shall be monitored to determine that its radioactivity cannot be distinguished from background with typical low-level laboratory survey instruments. All radiation labels will be removed or obliterated.

    C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

18. Sealed sources containing licensed material shall not be opened.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 16-03657-01

Docket or Reference number: 030-01748

Amendment No. 27

(Cont'd) CONDITIONS

19. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in applications dated March 1, 1985, May 9, 1985 and May 17, 1985. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

UNITED STATES NUCLEAR REGULATORY COMMISSION

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date JUL 03 1985

By PAUL R. GUINN

Region II, Nuclear Materials
Safety Section
101 Marietta Street, Suite 2900
Atlanta, GA 30323

CONVERSATION RECORD

TIME

DATE 6/27/85

TYPE
☐ VISIT ☐ CONFERENCE ☐ TELEPHONE
☐ INCOMING ☑ OUTGOING

Location of Visit/Conference:

NAME OF PERSON(S) CONTACTED OR IN CONTACT WITH YOU	ORGANIZATION (Office, dept., bureau, etc.)	TELEPHONE NO.
1LT John G. Monfre, Jr, MSS Rsc	Army Ft Knox, Ky	502 - 624-1143

ROUTING

NAME/SYMBOL	INT

SUBJECT
Renewal of License No. 16-03657-01
Obstacle Learning Night Vision testing.

SUMMARY

This device is used by doctor. To test Night Vision adaptobility of pilots and other military personnel

ACTION REQUIRED
Issue license with the night vision dev. on the license

NAME OF PERSON DOCUMENTING CONVERSATION
PAUL R. GUINN

SIGNATURE
Paul R. Guinn

DATE
6/27/85

ACTION TAKEN

SIGNATURE | TITLE | DATE

50271-101 CONVERSATION RECORD OPTIONAL FORM 271 (12-76) DEPARTMENT OF DEFENSE

DEPARTMENT OF THE ARMY
US ARMY MEDICAL DEPARTMENT ACTIVITY
Fort Knox, Kentucky 40121

HSXM-CD

17 May 1985

SUBJECT: Letter of Transmittal Amendment No. 27 to NRC License No. 16-03657-01

THRU: Commander
U.S. Army Health Services Command
ATTN: HSCL-P
Fort Sam Houston, Texas 78234-6000

TO: Office of the Surgeon General
ATTN: DASG-PSP-E
Washington, DC 20310

1. Request the processing of the enclosed NRC License Amendment request for NRC License Number 16-03657-01, USA MEDDAC, Fort Knox, Kentucky.

2. This amendment incorporates a new Radioimmunoassay work area into the license.

Encl

GEORGE W. WARD, JR.
Colonel, Medical Corps
Commanding